Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib.
about
Modulatory effects of bortezomib on host immune cell functionsRegulatory myeloid cells in transplantationRituximab-refractory thrombotic thrombocytopenic purpura responsive to intravenous but not subcutaneous bortezomib.Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura.Bortezomib therapy in patients with relapsed/refractory acquired thrombotic thrombocytopenic purpura.On to the road to degradation: atherosclerosis and the proteasomeDysfunction of the ubiquitin-proteasome system in atherosclerotic cardiovascular diseaseInduction of potent NK cell-dependent anti-myeloma cytotoxic T cells in response to combined mapatumumab and bortezomib.Bortezomib Improves Adoptive T-cell Therapy by Sensitizing Cancer Cells to FasL Cytotoxicity.Proteasome inhibition and allogeneic hematopoietic stem cell transplantation: a reviewDrug-mediated and cellular immunotherapy in multiple myeloma.Proteasome inhibitors as experimental therapeutics of autoimmune diseases.Selective apoptosis of monocytes and monocyte-derived DCs induced by bortezomib (Velcade).The proteasome inhibitor Velcade enhances rather than reduces disease in mouse hepatitis coronavirus-infected mice.Bortezomib: a new player in pre- and post-transplant desensitization?Proteasome inhibition induces apoptosis in primary human natural killer cells and suppresses NKp46-mediated cytotoxicity.Proteasome inhibitors for malignancy-related Lambert-Eaton myasthenic syndrome.Enumeration of blood dendritic cells in patients with multiple myeloma at presentation and through therapy.
P2860
Q26795618-27F40575-48A5-4DF4-A9D0-43E5D2F45259Q26999875-ACAD9407-4506-4B6C-BD29-CA7EA6BE682EQ33429298-16650448-CAFF-485C-8C76-11F1FCB62AC8Q33430998-E172E52D-7D6E-49C2-A43F-927A7E271AB2Q33435129-95EB184F-56F3-47D6-BBF8-0EF2BEA2375CQ33554513-98D9684E-6E4D-4608-9D00-0810265D2C27Q35659471-7A5EE0C0-3732-42A6-B7F7-23B56DEB9FC1Q36060298-82056A11-2D47-445C-82DE-E804221A6C4DQ36378038-A1D8FC1B-2F30-4F6A-A867-E3FD75A0FDD3Q36408216-59D77F24-F2AD-4182-BB71-747C114A42DBQ37773257-ACC6B497-5E2C-4922-9A1A-B75EF10D4199Q38427697-D7FC6E85-904F-4506-B1A0-15403BC33070Q39937379-EA1246F5-E552-4882-BE6C-CA39CD0853ABQ42738022-431556A1-9F12-44D3-902A-57F3EEEB7FE8Q42913151-02199ECD-5F89-4521-9383-835E710103DDQ43152799-E98CC463-65D7-419D-830E-C1496139DD54Q43716462-78D141CE-A86D-4414-A04E-2367355CEA62Q46216910-30E02F54-4A6C-49AE-A8EB-524F696E3030
P2860
Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Dendritic cell maturation stag ...... oteasome inhibitor bortezomib.
@en
Dendritic cell maturation stag ...... oteasome inhibitor bortezomib.
@nl
type
label
Dendritic cell maturation stag ...... oteasome inhibitor bortezomib.
@en
Dendritic cell maturation stag ...... oteasome inhibitor bortezomib.
@nl
prefLabel
Dendritic cell maturation stag ...... oteasome inhibitor bortezomib.
@en
Dendritic cell maturation stag ...... oteasome inhibitor bortezomib.
@nl
P2093
P1433
P1476
Dendritic cell maturation stag ...... oteasome inhibitor bortezomib.
@en
P2093
Andreas Lietz
Antonio Pezzutto
Bernd Dörken
Carola Beier
Kathrin Sebelin-Wulf
Marion Subklewe
Stephan Mathas
P304
P356
10.1016/J.HUMIMM.2006.12.005
P577
2007-01-04T00:00:00Z